Stockreport

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 [Yahoo! Fin...

Kezar Life Sciences, Inc.  (KZR) 
Last kezar life sciences, inc. earnings: 8/7 04:05 pm Check Earnings Report
PDF novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial [Read more]